← Leaderboards
William Russell Renthal
Brigham And Women'S Hospital
$13,505,744
Attributed
$16,893,564
Total exposure
10
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $6.7M · FY2017–25$10M$7.5M$5M$2.5M$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$27,264,175 · 11
By mechanism
U19$15,811,817 · 7
U01$5,081,730 · 1
R01$2,745,930 · 1
DP1$2,685,000 · 1
K08$939,698 · 1
Top collaborators
- Pedram Hamrah4 shared
- Ian D Meng4 shared
- Clifford J Woolf4 shared
Most similar at Brigham And Women'S Hospital
Same institution · by research overlap
- William M Wells$5,899,370
- Kyle Eberlin$981,310
- Xianjun Dong$5,508,506
- Joshua K Lin$16,782,382
- Laura McGrath Holsen$5,208,156
Others in their field
Other Emerging Leaders on “Cells”
- Douglas S. Hawkins · Children'S Hosp Of Philadelphia$155,695,588
- Gautam (george) Mitra · Leidos Biomedical Research, Inc.$53,523,213
- Evan Z Macosko · Broad Institute, Inc.$33,096,828
- James Dale Berry · Brigham And Women'S Hospital$30,122,905
- Hanjoon Ryu$28,519,898
- Eric C Palm · Florida State University$26,502,247
Research focus
CellsNeuronsPainGene ExpressionGenesEpigenomicsChronic PainCell TypeTissuesResolutionAnimal ModelAffectPain ClinicsInsightPain ModelProtocols DocumentationSensory GangliaComplexNociceptorsDesignGenetic TranscriptionMolecularEnsureSampling
Grant awards (35)
Harvard PRECISION Human Pain Center$2,570,113
U19 · FY2025 · NS · contact PI
Central and Peripheral Mechanisms of Corneal Pain$1,117,237
U01 · FY2025 · EY
Multi-Omics Core$685,262
U19 · FY2025 · NS · contact PI
Next Generation Gene Therapy for Refractory Pain$634,215
R01 · FY2025 · NS · contact PI
Epigenomic labeling of cells that drive drug abuse behavior$537,000
DP1 · FY2025 · DA · contact PI
Project 1: Multi-omic characterization of human nociceptors$397,664
U19 · FY2025 · NS · contact PI
Administrative Core$181,243
U19 · FY2025 · NS · contact PI
Harvard PRECISION Human Pain Center$2,574,551
U19 · FY2024 · NS · contact PI
Central and Peripheral Mechanisms of Corneal Pain$1,314,396
U01 · FY2024 · EY
Next Generation Gene Therapy for Refractory Pain$688,317
R01 · FY2024 · NS · contact PI
Multi-Omics Core$685,262
U19 · FY2024 · NS · contact PI
Epigenomic labeling of cells that drive drug abuse behavior$537,000
DP1 · FY2024 · DA · contact PI
Project 1: Multi-omic characterization of human nociceptors$399,883
U19 · FY2024 · NS · contact PI
Administrative Core$181,243
U19 · FY2024 · NS · contact PI
Harvard PRECISION Human Pain Center$2,578,553
U19 · FY2023 · NS · contact PI
Central and Peripheral Mechanisms of Corneal Pain$1,314,396
U01 · FY2023 · EY
Multi-Omics Core$849,301
U19 · FY2023 · NS · contact PI
Next Generation Gene Therapy for Refractory Pain$711,525
R01 · FY2023 · NS · contact PI
Epigenomic labeling of cells that drive drug abuse behavior$537,000
DP1 · FY2023 · DA · contact PI
Project 1: Multi-omic characterization of human nociceptors$444,518
U19 · FY2023 · NS · contact PI
Administrative Core$181,243
U19 · FY2023 · NS · contact PI
Harvard PRECISION Human Pain Center$2,647,394
U19 · FY2022 · NS · contact PI
Central and Peripheral Mechanisms of Corneal Pain$1,335,701
U01 · FY2022 · EY
Multi-Omics Core$810,562
U19 · FY2022 · NS · contact PI
Next generation gene therapy for refractory pain$711,873
R01 · FY2022 · NS · contact PI
Epigenomic labeling of cells that drive drug abuse behavior$537,000
DP1 · FY2022 · DA · contact PI
Project 1: Multi-omic characterization of human nociceptors$423,880
U19 · FY2022 · NS · contact PI
Administrative Core$201,145
U19 · FY2022 · NS · contact PI
Epigenomic labeling of cells that drive drug abuse behavior$537,000
DP1 · FY2021 · DA · contact PI
CONTROL OF LONG GENE EXPRESSION AS A NOVEL THERAPEUTIC APPROACH FOR RETT SYNDROME$197,640
K08 · FY2021 · NS · contact PI
CONTROL OF LONG GENE EXPRESSION AS A NOVEL THERAPEUTIC APPROACH FOR RETT SYNDROME$197,640
K08 · FY2020 · NS · contact PI
CONTROL OF LONG GENE EXPRESSION AS A NOVEL THERAPEUTIC APPROACH FOR RETT SYNDROME$162,000
K08 · FY2019 · NS · contact PI
Control of long gene expression as a novel therapeutic approach for Rett syndrome$19,806
K08 · FY2019 · NS · contact PI
Control of long gene expression as a novel therapeutic approach for Rett syndrome$181,806
K08 · FY2018 · NS · contact PI
Control of long gene expression as a novel therapeutic approach for Rett syndrome$180,806
K08 · FY2017 · NS · contact PI